FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010621423> ?p ?o ?g. }

• W2010621423 endingPage "703" @default.
• W2010621423 startingPage "699" @default.
• W2010621423 abstract "Background: The use of metabolic drugs effective in addition to conventional therapy represents a significant challenge in patients with left ventricular dysfunction. Hypothesis: The aim of this double-blind, placebo-controlled study was to investigate the hemodynamic effects of acute intravenous (IV) administration of creatine phosphate (CP) and of short-term treatment in patients with congestive heart failure (CHF) from ischemic heart disease (IHD) or dilated cardiomyopathy in addition to conventional therapy. Methods: We compared the hemodynamic effects of exogenous creatine phosphate (CP) and placebo in a double-blind, crossover design study in 13 hospitalized patients (12 men, 1 woman, mean age 52 ± 8 years) with CHF. All patients were in New York Heart Association (NYHA) class II-III and received conventional pharmacologic therapy for CHF this was not changed during the study period. The study design consisted of two treatment periods (CP or placebo and placebo or CP, respectively) of 4 days each, separated by a 2-day washout interval. The intravenous infusion consisted of 6 g CP or placebo (acute treatment) or 6 g CP or placebo daily for 4 days (short-term treatment) diluted in 50 ml of NaCl 0.9%;infusion duration was about 10 min. Mono-bidimensional echocardiographic examination (Hewlett Packard So-nos 1000, with a 2.5 MHz transducer) was performed at baseline, after acute infusion, and 12 h after the end of short-term treatment. Data were analyzed by ANOVA and Student's t-test for paired data the results obtained after acute and short-term therapy were compared with the baseline values. Results: After placebo therapy, no significant change was observed. The results after treatment with CP showed a significant reduction of end-systolic diameter [baseline: 4.5 ± 0.6;acute: 4.2 ± 0.5, (p<0.001);short-term 4.3 ± 0.6 cm, (p<0.05)] and systemic vascular resistance (baseline: 1064.9 ± 483.7;acute: 947.5 ± 390.2 (p<0.05);short-term: 950.7 ± 394.3 dynescm-5 (p<0.05);moreover, a significant increase of percent ejection fraction [baseline:48 ± 12%;acute 53 ± 12% (p<0.01);short-term 52 ± 11 % (p<0.01)], and of percent fractional shortening [baseline: 25 ± 7;acute 28 ± 8 (p<0.05);short-term 28 ± 7% (p<0.05)] was observed. Conclusion: CP was shown to improve cardiac function, even in the presence of a conventional CHF pharmacologic therapy." @default.
• W2010621423 created "2016-06-24" @default.
• W2010621423 creator A5001116274 @default.
• W2010621423 creator A5020160064 @default.
• W2010621423 creator A5026695170 @default.
• W2010621423 creator A5031520214 @default.
• W2010621423 creator A5051324603 @default.
• W2010621423 creator A5062162284 @default.
• W2010621423 creator A5070577688 @default.
• W2010621423 date "1996-09-01" @default.
• W2010621423 modified "2023-09-27" @default.
• W2010621423 title "Hemodynamic effects of creatine phosphate in patients with congestive heart failure: A double-blind comparison trial versus placebo" @default.
• W2010621423 cites W1967473422 @default.
• W2010621423 cites W1967612576 @default.
• W2010621423 cites W1974395224 @default.
• W2010621423 cites W1975792971 @default.
• W2010621423 cites W1977158456 @default.
• W2010621423 cites W1986764252 @default.
• W2010621423 cites W2015713490 @default.
• W2010621423 cites W2023239744 @default.
• W2010621423 cites W2023492589 @default.
• W2010621423 cites W2025798145 @default.
• W2010621423 cites W2026415733 @default.
• W2010621423 cites W2026846976 @default.
• W2010621423 cites W2033292054 @default.
• W2010621423 cites W2036505470 @default.
• W2010621423 cites W2044523254 @default.
• W2010621423 cites W2051862900 @default.
• W2010621423 cites W2058212943 @default.
• W2010621423 cites W2060865242 @default.
• W2010621423 cites W2071638007 @default.
• W2010621423 cites W2081133653 @default.
• W2010621423 cites W2107567775 @default.
• W2010621423 cites W2110199703 @default.
• W2010621423 cites W2130806342 @default.
• W2010621423 cites W2405528502 @default.
• W2010621423 cites W2410005511 @default.
• W2010621423 cites W4317926856 @default.
• W2010621423 doi "https://doi.org/10.1002/clc.4960190905" @default.
• W2010621423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8874988" @default.
• W2010621423 hasPublicationYear "1996" @default.
• W2010621423 type Work @default.
• W2010621423 sameAs 2010621423 @default.
• W2010621423 citedByCount "18" @default.
• W2010621423 countsByYear W20106214232012 @default.
• W2010621423 countsByYear W20106214232014 @default.
• W2010621423 countsByYear W20106214232017 @default.
• W2010621423 countsByYear W20106214232019 @default.
• W2010621423 countsByYear W20106214232020 @default.
• W2010621423 countsByYear W20106214232021 @default.
• W2010621423 crossrefType "journal-article" @default.
• W2010621423 hasAuthorship W2010621423A5001116274 @default.
• W2010621423 hasAuthorship W2010621423A5020160064 @default.
• W2010621423 hasAuthorship W2010621423A5026695170 @default.
• W2010621423 hasAuthorship W2010621423A5031520214 @default.
• W2010621423 hasAuthorship W2010621423A5051324603 @default.
• W2010621423 hasAuthorship W2010621423A5062162284 @default.
• W2010621423 hasAuthorship W2010621423A5070577688 @default.
• W2010621423 hasConcept C126322002 @default.
• W2010621423 hasConcept C142724271 @default.
• W2010621423 hasConcept C164705383 @default.
• W2010621423 hasConcept C178853913 @default.
• W2010621423 hasConcept C204787440 @default.
• W2010621423 hasConcept C27081682 @default.
• W2010621423 hasConcept C2778198053 @default.
• W2010621423 hasConcept C2779896295 @default.
• W2010621423 hasConcept C2780074459 @default.
• W2010621423 hasConcept C42219234 @default.
• W2010621423 hasConcept C71924100 @default.
• W2010621423 hasConcept C87813604 @default.
• W2010621423 hasConceptScore W2010621423C126322002 @default.
• W2010621423 hasConceptScore W2010621423C142724271 @default.
• W2010621423 hasConceptScore W2010621423C164705383 @default.
• W2010621423 hasConceptScore W2010621423C178853913 @default.
• W2010621423 hasConceptScore W2010621423C204787440 @default.
• W2010621423 hasConceptScore W2010621423C27081682 @default.
• W2010621423 hasConceptScore W2010621423C2778198053 @default.
• W2010621423 hasConceptScore W2010621423C2779896295 @default.
• W2010621423 hasConceptScore W2010621423C2780074459 @default.
• W2010621423 hasConceptScore W2010621423C42219234 @default.
• W2010621423 hasConceptScore W2010621423C71924100 @default.
• W2010621423 hasConceptScore W2010621423C87813604 @default.
• W2010621423 hasIssue "9" @default.
• W2010621423 hasLocation W20106214231 @default.
• W2010621423 hasLocation W20106214232 @default.
• W2010621423 hasOpenAccess W2010621423 @default.
• W2010621423 hasPrimaryLocation W20106214231 @default.
• W2010621423 hasRelatedWork W193675009 @default.
• W2010621423 hasRelatedWork W1970739197 @default.
• W2010621423 hasRelatedWork W2010621423 @default.
• W2010621423 hasRelatedWork W2125804349 @default.
• W2010621423 hasRelatedWork W2149962743 @default.
• W2010621423 hasRelatedWork W2385904810 @default.
• W2010621423 hasRelatedWork W2398968602 @default.
• W2010621423 hasRelatedWork W2736014237 @default.
• W2010621423 hasRelatedWork W2807621544 @default.
• W2010621423 hasRelatedWork W3001274119 @default.
• W2010621423 hasVolume "19" @default.

• next